Abituzumab
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type) . Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1].
Product Specifications
CAS Number
1105038-73-0
Product Name Alternative
EMD 525797; DI17E6
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/abituzumab.html
Purity
99.38
Solubility
10 mM in DMSO
Smiles
[Abituzumab]
Molecular Weight
(144.58 kDa)
References & Citations
[1]Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15 (7) :875-883.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
JOT-EK5364Hu-01 48 Well
Human Growth;differentiation factor 6,GDF6 ELISA KIT
Sign In for Pricing
View Details JOT-EK5364Hu-02 96 Well
Human Growth;differentiation factor 6,GDF6 ELISA KIT
Sign In for Pricing
View Details 
